The  ||| S:0 E:4 ||| DT
use  ||| S:4 E:8 ||| NN
of  ||| S:8 E:11 ||| IN
integrase  ||| S:11 E:21 ||| JJ
inhibitors  ||| S:21 E:32 ||| NN
in  ||| S:32 E:35 ||| IN
treatment-experienced  ||| S:35 E:57 ||| JJ
patients  ||| S:57 E:66 ||| NNS
Raltegravir ||| S:66 E:77 ||| NNP
,  ||| S:77 E:79 ||| ,
the  ||| S:79 E:83 ||| DT
first  ||| S:83 E:89 ||| JJ
approved  ||| S:89 E:98 ||| FW
HIV-1  ||| S:98 E:104 ||| FW
integrase  ||| S:104 E:114 ||| FW
inhibitor ||| S:114 E:123 ||| FW
,  ||| S:123 E:125 ||| ,
is  ||| S:125 E:128 ||| VBZ
able  ||| S:128 E:133 ||| JJ
to  ||| S:133 E:136 ||| TO
block  ||| S:136 E:142 ||| VB
the  ||| S:142 E:146 ||| DT
strand  ||| S:146 E:153 ||| JJ
transfer  ||| S:153 E:162 ||| NN
step  ||| S:162 E:167 ||| NN
of  ||| S:167 E:170 ||| IN
the  ||| S:170 E:174 ||| DT
HIV  ||| S:174 E:178 ||| NNP
proviral  ||| S:178 E:187 ||| JJ
DNA  ||| S:187 E:191 ||| NN
integration  ||| S:191 E:203 ||| NN
process  ||| S:203 E:211 ||| NN
into  ||| S:211 E:216 ||| IN
the  ||| S:216 E:220 ||| DT
cellular  ||| S:220 E:229 ||| JJ
host  ||| S:229 E:234 ||| NN
DNA ||| S:234 E:237 ||| NN
.  ||| S:237 E:239 ||| .
The  ||| S:239 E:243 ||| DT
selected  ||| S:243 E:252 ||| JJ
dosage  ||| S:252 E:259 ||| NN
for  ||| S:259 E:263 ||| IN
the  ||| S:263 E:267 ||| DT
pivotal  ||| S:267 E:275 ||| JJ
phase  ||| S:275 E:281 ||| NN
III  ||| S:281 E:285 ||| NNP
studies  ||| S:285 E:293 ||| NNS
( ||| S:293 E:294 ||| -LRB-
subsequently  ||| S:294 E:307 ||| RB
approved  ||| S:307 E:316 ||| VBN
by  ||| S:316 E:319 ||| IN
the  ||| S:319 E:323 ||| DT
regulatory  ||| S:323 E:334 ||| JJ
agencies ||| S:334 E:342 ||| NNS
)  ||| S:342 E:344 ||| -RRB-
was  ||| S:344 E:348 ||| VBD
400mg  ||| S:348 E:354 ||| CD
bid  ||| S:354 E:358 ||| NN
by  ||| S:358 E:361 ||| IN
oral  ||| S:361 E:366 ||| JJ
route  ||| S:366 E:372 ||| NN
with  ||| S:372 E:377 ||| IN
or  ||| S:377 E:380 ||| CC
without  ||| S:380 E:388 ||| IN
food ||| S:388 E:392 ||| NN
.  ||| S:392 E:394 ||| .
Raltegravir  ||| S:394 E:406 ||| NNP
has  ||| S:406 E:410 ||| VBZ
a  ||| S:410 E:412 ||| DT
week  ||| S:412 E:417 ||| NN
effect  ||| S:417 E:424 ||| NN
( ||| S:424 E:425 ||| -LRB-
either  ||| S:425 E:432 ||| DT
inhibition  ||| S:432 E:443 ||| NN
or  ||| S:443 E:446 ||| CC
induction ||| S:446 E:455 ||| CD
)  ||| S:455 E:457 ||| -RRB-
on  ||| S:457 E:460 ||| IN
the  ||| S:460 E:464 ||| DT
hepatic  ||| S:464 E:472 ||| JJ
cytochrone  ||| S:472 E:483 ||| NN
P450  ||| S:483 E:488 ||| CD
activity ||| S:488 E:496 ||| NN
.  ||| S:496 E:498 ||| .
There  ||| S:498 E:504 ||| EX
is  ||| S:504 E:507 ||| VBZ
not  ||| S:507 E:511 ||| RB
need  ||| S:511 E:516 ||| VB
of  ||| S:516 E:519 ||| IN
dose  ||| S:519 E:524 ||| NN
adjustments  ||| S:524 E:536 ||| NNS
in  ||| S:536 E:539 ||| IN
renal  ||| S:539 E:545 ||| JJ
insufficiency  ||| S:545 E:559 ||| NN
or  ||| S:559 E:562 ||| CC
in  ||| S:562 E:565 ||| IN
mild-to-moderate  ||| S:565 E:582 ||| JJ
hepatic  ||| S:582 E:590 ||| JJ
impairment ||| S:590 E:600 ||| NN
.  ||| S:600 E:602 ||| .
The  ||| S:602 E:606 ||| DT
emerging  ||| S:606 E:615 ||| VBG
paradigm  ||| S:615 E:624 ||| NN
in  ||| S:624 E:627 ||| IN
the  ||| S:627 E:631 ||| DT
field  ||| S:631 E:637 ||| NN
of  ||| S:637 E:640 ||| IN
salvage  ||| S:640 E:648 ||| JJ
therapy  ||| S:648 E:656 ||| NN
was  ||| S:656 E:660 ||| VBD
to  ||| S:660 E:663 ||| TO
achieve  ||| S:663 E:671 ||| VB
a  ||| S:671 E:673 ||| DT
viral  ||| S:673 E:679 ||| JJ
load  ||| S:679 E:684 ||| NN
below  ||| S:684 E:690 ||| IN
limit  ||| S:690 E:696 ||| NN
of  ||| S:696 E:699 ||| IN
detection  ||| S:699 E:709 ||| NN
in  ||| S:709 E:712 ||| IN
almost  ||| S:712 E:719 ||| RB
all  ||| S:719 E:723 ||| DT
patients ||| S:723 E:731 ||| NNS
.  ||| S:731 E:733 ||| .
Pretty  ||| S:733 E:740 ||| RB
soon  ||| S:740 E:745 ||| RB
it  ||| S:745 E:748 ||| PRP
became  ||| S:748 E:755 ||| VBD
apparent  ||| S:755 E:764 ||| JJ
that  ||| S:764 E:769 ||| IN
this  ||| S:769 E:774 ||| DT
was  ||| S:774 E:778 ||| VBD
feasible  ||| S:778 E:787 ||| VBN
in  ||| S:787 E:790 ||| IN
more  ||| S:790 E:795 ||| JJR
than  ||| S:795 E:800 ||| IN
70-90 ||| S:800 E:805 ||| CD
%  ||| S:805 E:807 ||| NN
of  ||| S:807 E:810 ||| IN
patients ||| S:810 E:818 ||| NNS
.  ||| S:818 E:820 ||| .
Raltegravir  ||| S:820 E:832 ||| NNP
proved  ||| S:832 E:839 ||| VBD
to  ||| S:839 E:842 ||| TO
be  ||| S:842 E:845 ||| VB
pivotal  ||| S:845 E:853 ||| VBN
for  ||| S:853 E:857 ||| IN
this  ||| S:857 E:862 ||| DT
new  ||| S:862 E:866 ||| JJ
paradigm ||| S:866 E:874 ||| NN
.  ||| S:874 E:876 ||| .
Raltegravir  ||| S:876 E:888 ||| JJ
vs  ||| S:888 E:891 ||| JJ
placebo  ||| S:891 E:899 ||| NN
both  ||| S:899 E:904 ||| CC
with  ||| S:904 E:909 ||| IN
an  ||| S:909 E:912 ||| DT
optimized  ||| S:912 E:922 ||| JJ
background  ||| S:922 E:933 ||| NN
therapy  ||| S:933 E:941 ||| NN
has  ||| S:941 E:945 ||| VBZ
been  ||| S:945 E:950 ||| VBN
tested  ||| S:950 E:957 ||| VBN
for  ||| S:957 E:961 ||| IN
salvage  ||| S:961 E:969 ||| JJ
therapy  ||| S:969 E:977 ||| NN
in  ||| S:977 E:980 ||| IN
the  ||| S:980 E:984 ||| DT
005  ||| S:984 E:988 ||| CD
and  ||| S:988 E:992 ||| CC
in  ||| S:992 E:995 ||| IN
the  ||| S:995 E:999 ||| DT
BENCHMRK  ||| S:999 E:1008 ||| NNP
studies  ||| S:1008 E:1016 ||| NNS
( ||| S:1016 E:1017 ||| -LRB-
018  ||| S:1017 E:1021 ||| CD
and  ||| S:1021 E:1025 ||| CC
019 ||| S:1025 E:1028 ||| CD
) ||| S:1028 E:1029 ||| -RRB-
.  ||| S:1029 E:1031 ||| .
In  ||| S:1031 E:1034 ||| IN
all  ||| S:1034 E:1038 ||| DT
three  ||| S:1038 E:1044 ||| CD
studies  ||| S:1044 E:1052 ||| NNS
proved  ||| S:1052 E:1059 ||| VBD
to  ||| S:1059 E:1062 ||| TO
be  ||| S:1062 E:1065 ||| VB
superior  ||| S:1065 E:1074 ||| JJ
to  ||| S:1074 E:1077 ||| TO
the  ||| S:1077 E:1081 ||| DT
placebo  ||| S:1081 E:1089 ||| NN
at  ||| S:1089 E:1092 ||| IN
24 ||| S:1092 E:1094 ||| CD
,  ||| S:1094 E:1096 ||| ,
48  ||| S:1096 E:1099 ||| CD
and  ||| S:1099 E:1103 ||| CC
96  ||| S:1103 E:1106 ||| CD
weeks ||| S:1106 E:1111 ||| NNS
.  ||| S:1111 E:1113 ||| .
Tolerance  ||| S:1113 E:1123 ||| NNP
was  ||| S:1123 E:1127 ||| VBD
remarkably  ||| S:1127 E:1138 ||| RB
good  ||| S:1138 E:1143 ||| JJ
and  ||| S:1143 E:1147 ||| CC
virological  ||| S:1147 E:1159 ||| JJ
failure  ||| S:1159 E:1167 ||| NN
was  ||| S:1167 E:1171 ||| VBD
often  ||| S:1171 E:1177 ||| RB
associated  ||| S:1177 E:1188 ||| VBN
with  ||| S:1188 E:1193 ||| IN
selection  ||| S:1193 E:1203 ||| NN
of  ||| S:1203 E:1206 ||| IN
integrase  ||| S:1206 E:1216 ||| JJ
gene  ||| S:1216 E:1221 ||| NN
resistance  ||| S:1221 E:1232 ||| NN
mutations  ||| S:1232 E:1242 ||| NNS
following  ||| S:1242 E:1252 ||| VBG
the  ||| S:1252 E:1256 ||| DT
Y143C ||| S:1256 E:1261 ||| NNP
/ ||| S:1261 E:1262 ||| NNP
H ||| S:1262 E:1263 ||| NNP
/ ||| S:1263 E:1264 ||| NNP
R ||| S:1264 E:1265 ||| NNP
,  ||| S:1265 E:1267 ||| ,
Q148H ||| S:1267 E:1272 ||| NNP
/ ||| S:1272 E:1273 ||| NNP
K ||| S:1273 E:1274 ||| NNP
/ ||| S:1274 E:1275 ||| NNP
R  ||| S:1275 E:1277 ||| NNP
o  ||| S:1277 E:1279 ||| VBD
less  ||| S:1279 E:1284 ||| RBR
frequently  ||| S:1284 E:1295 ||| RB
the  ||| S:1295 E:1299 ||| DT
NI55H  ||| S:1299 E:1305 ||| CD
paths ||| S:1305 E:1310 ||| NNS
.  ||| S:1310 E:1312 ||| .
Finally ||| S:1312 E:1319 ||| RB
,  ||| S:1319 E:1321 ||| ,
in  ||| S:1321 E:1324 ||| IN
the  ||| S:1324 E:1328 ||| DT
two  ||| S:1328 E:1332 ||| CD
SWITCHMRK  ||| S:1332 E:1342 ||| FW
studies  ||| S:1342 E:1350 ||| FW
non-inferiority  ||| S:1350 E:1366 ||| FW
vs  ||| S:1366 E:1369 ||| FW
Lopinavir ||| S:1369 E:1378 ||| FW
/ ||| S:1378 E:1379 ||| FW
r  ||| S:1379 E:1381 ||| FW
could  ||| S:1381 E:1387 ||| MD
not  ||| S:1387 E:1391 ||| RB
be  ||| S:1391 E:1394 ||| VB
demonstrated  ||| S:1394 E:1407 ||| VBN
in  ||| S:1407 E:1410 ||| IN
virogically  ||| S:1410 E:1422 ||| JJ
suppressed  ||| S:1422 E:1433 ||| JJ
patients  ||| S:1433 E:1442 ||| NNS
with  ||| S:1442 E:1447 ||| IN
an  ||| S:1447 E:1450 ||| DT
stable  ||| S:1450 E:1457 ||| JJ
cART  ||| S:1457 E:1462 ||| FW
containing  ||| S:1462 E:1473 ||| FW
Lopinavir ||| S:1473 E:1482 ||| FW
/ ||| S:1482 E:1483 ||| FW
r ||| S:1483 E:1484 ||| FW
.  ||| S:1484 E:1486 ||| .
Most  ||| S:1486 E:1491 ||| RBS
likely  ||| S:1491 E:1498 ||| JJ
explanation  ||| S:1498 E:1510 ||| NN
was  ||| S:1510 E:1514 ||| VBD
the  ||| S:1514 E:1518 ||| DT
presence  ||| S:1518 E:1527 ||| NN
of  ||| S:1527 E:1530 ||| IN
archived  ||| S:1530 E:1539 ||| JJ
resistance  ||| S:1539 E:1550 ||| NN
mutationts  ||| S:1550 E:1561 ||| NN
to  ||| S:1561 E:1564 ||| TO
background  ||| S:1564 E:1575 ||| NN
therapy  ||| S:1575 E:1583 ||| NN
leading  ||| S:1583 E:1591 ||| VBG
to  ||| S:1591 E:1594 ||| TO
a  ||| S:1594 E:1596 ||| DT
functional  ||| S:1596 E:1607 ||| JJ
monotherapy  ||| S:1607 E:1619 ||| NN
with  ||| S:1619 E:1624 ||| IN
raltegravir ||| S:1624 E:1635 ||| NN
.  ||| S:1635 E:1637 ||| .
